Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Free Cash Flow (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Free Cash Flow for 13 consecutive years, with -$114.0 million as the latest value for Q1 2026.

  • For Q1 2026, Free Cash Flow fell 117.8% year-over-year to -$114.0 million; the TTM value through Mar 2026 reached -$340.3 million, down 154.0%, while the annual FY2025 figure was -$278.7 million, 217.45% down from the prior year.
  • Free Cash Flow hit -$114.0 million in Q1 2026 for Viking Therapeutics, down from -$85.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$6.1 million in Q1 2024 and bottomed at -$114.0 million in Q1 2026.
  • Average Free Cash Flow over 5 years is -$35.4 million, with a median of -$22.0 million recorded in 2024.
  • Year-over-year, Free Cash Flow skyrocketed 75.11% in 2024 and then tumbled 753.13% in 2025.
  • Viking Therapeutics' Free Cash Flow stood at -$10.9 million in 2022, then tumbled by 61.45% to -$17.6 million in 2023, then crashed by 76.76% to -$31.2 million in 2024, then crashed by 173.53% to -$85.3 million in 2025, then tumbled by 33.63% to -$114.0 million in 2026.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$114.0 million, -$85.3 million, and -$94.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.